Journal of Clinical Oncology via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Journal of Clinical Oncology' source. Sat, 20 Mar 2010 13:50:41 +0100 The American Society of Clinical Oncology Cancer Foundation Grants Program: A 25-Year Report and a Look Toward the Future [SPECIAL ARTICLE] http://www.medworm.com/index.php?rid=3380024&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1616%3Frss%3D1 This article, celebrating the 25th anniversary of this initiative, describes the history and evolution of the Grants Program, attempts to measure the impact of the program on clinical cancer research through an analysis of the career paths of past recipients, and addresses challenges that the program will face as it enters its second 25 years. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380024 Thu, 18 Mar 2010 22:01:37 +0100 3380024 Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3380023&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1611%3Frss%3D1 Conclusion Six cycles of ABVD is an effective and safe treatment for limited-stage, nonbulky HL and would spare young patients radiation toxicity. Interim positron emission tomography/computed tomography scans in current and future trials may identify those patients who require less than six cycles of chemotherapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380023 Thu, 18 Mar 2010 22:01:37 +0100 3380023 Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3380022&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1606%3Frss%3D1 Conclusion We recommend use of wb-MRI for risk stratification of patients with asymptomatic multiple myeloma. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380022 Thu, 18 Mar 2010 22:01:37 +0100 3380022 Reply to I. Abraham [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3379996&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2Fe145%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379996 Thu, 18 Mar 2010 22:01:37 +0100 3379996 Intravenous Bisphosphonate Treatment and Osteonecrosis of the Jaw in Patients With Cancer: Wide CIs, Yule-Simpson and King Kong Effects, and No Therapeutic Outcomes [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3379995&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2Fe143%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379995 Thu, 18 Mar 2010 22:01:37 +0100 3379995 Reply to D.E. Gyorki et al and P.J. van Diest et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3379994&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2Fe141%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379994 Thu, 18 Mar 2010 22:01:37 +0100 3379994 Micrometastases and Isolated Tumor Cells in Breast Cancer Are Indeed Associated With Poorer Outcome [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3379993&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2Fe140%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379993 Thu, 18 Mar 2010 22:01:37 +0100 3379993 Significance of Sentinel Lymph Node Micrometastases in Patients With Breast Cancer [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3379992&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2Fe139%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379992 Thu, 18 Mar 2010 22:01:37 +0100 3379992 Burkitt's Lymphoma in Early Pregnancy [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=3379991&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2Fe136%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379991 Thu, 18 Mar 2010 22:01:37 +0100 3379991 Pulmonary Calciphylaxis and Metastatic Calcification With Acute Respiratory Failure in Multiple Myeloma [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=3379990&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2Fe133%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379990 Thu, 18 Mar 2010 22:01:37 +0100 3379990 Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3380021&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1599%3Frss%3D1 Conclusion Age is associated with higher ISS stage and is an important risk factor for early mortality. Survival declined continuously by each decade from age 50 to age ≥ 80 from more than 6 to less than 3 years. The average of years of life lost in patients with myeloma is higher than in many other cancers and amounts to more than 30 years in patients younger than 40 years old but decreases to less than 5 years in patients age 80 years or older. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380021 Thu, 18 Mar 2010 22:01:36 +0100 3380021 Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3380020&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1591%3Frss%3D1 Conclusion KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL or PTCL. Subsequent phase II studies at the 1.0 mg/kg dose are thus warranted. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380020 Thu, 18 Mar 2010 22:01:36 +0100 3380020 Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3380019&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1583%3Frss%3D1 Conclusion We proved that experimentally controlled GEP in ALCL cell lines represents a powerful tool to identify meaningful signaling networks for the recognition of systemic primary T-NHL. The identification of a molecular signature specific for ALCL suggests that these T-NHLs may represent a unique entity discernible from other PTCLs, and that a restricted number of genes can be instrumental for clinical stratification and, possibly, therapy of T-NHL. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380019 Thu, 18 Mar 2010 22:01:36 +0100 3380019 Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group [Translational Oncology] http://www.medworm.com/index.php?rid=3380018&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1573%3Frss%3D1 Conclusion The presence of specific genetic aberrations was strongly associated with poor survival independent of known clinical risk factors. Conversely, within the total patient cohort with 34% 10-year disease-specific survival, a low-risk group was identified: without changes at chromosomes 10q, 16p, or Xq in their MPNSTs, the patients had 74% 10-year survival. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380018 Thu, 18 Mar 2010 22:01:36 +0100 3380018 Early Detection of Superficial Squamous Cell Carcinoma in the Head and Neck Region and Esophagus by Narrow Band Imaging: A Multicenter Randomized Controlled Trial [Head and Neck Cancer] http://www.medworm.com/index.php?rid=3380017&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1566%3Frss%3D1 Conclusion NBI could be the standard examination for the early detection of superficial cancer in the H&N region and the esophagus. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380017 Thu, 18 Mar 2010 22:01:36 +0100 3380017 Meeting Expectations of Patients With Cancer: Relationship Between Patient Satisfaction, Depression, and Coping [Palliative and Supportive Care] http://www.medworm.com/index.php?rid=3380016&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1560%3Frss%3D1 Conclusion Given the importance of patient satisfaction to treatment compliance, oncologists should consider evaluating patient expectations for support, especially in issues concerning planning the treatment and involving the family in medical decisions. Oncologists should take into account the possible interdependence between psychological variables and medical-care satisfaction. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380016 Thu, 18 Mar 2010 22:01:36 +0100 3380016 Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib [Sarcomas] http://www.medworm.com/index.php?rid=3380015&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1554%3Frss%3D1 Conclusion In patients with GIST, imatinib Cmin at steady state was significantly associated with albumin concentration, creatinine clearance, and previous major gastrectomy. Although its clinical impact is unclear at present time, monitoring of imatinib Cmin might be particularly important for optimal treatment with imatinib in patients who have undergone major gastrectomy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380015 Thu, 18 Mar 2010 22:01:36 +0100 3380015 Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=3380014&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1547%3Frss%3D1 Conclusion Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380014 Thu, 18 Mar 2010 22:01:36 +0100 3380014 Lung Cancer and Hormone Replacement Therapy: Association in the Vitamins and Lifestyle Study [Thoracic Oncology] http://www.medworm.com/index.php?rid=3380013&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1540%3Frss%3D1 Conclusion Use of E+P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380013 Thu, 18 Mar 2010 22:01:36 +0100 3380013 Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy [Thoracic Oncology] http://www.medworm.com/index.php?rid=3380012&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1534%3Frss%3D1 Conclusion In patients with MPM treated with P-based chemotherapy, low TS protein levels are predictive of improved TTP and OS. The role of TS assessment is worth of prospective validation in future studies on MPM. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380012 Thu, 18 Mar 2010 22:01:36 +0100 3380012 Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer [Thoracic Oncology] http://www.medworm.com/index.php?rid=3380011&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1527%3Frss%3D1 Conclusion Dulanermin plus PCB was well tolerated with no occurrence of DLTs and demonstrated antitumor activity in this patient population. Dulanermin at 8 mg/kg/d for 5 days and 20 mg/kg/d for 2 days every 3 weeks in combination with PCB is being studied in a phase II trial. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380011 Thu, 18 Mar 2010 22:01:36 +0100 3380011 Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors [Phase I and Clinical Pharmacology] http://www.medworm.com/index.php?rid=3380010&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1520%3Frss%3D1 Conclusion The recommended phase II doses of 17DMAG (16 mg/m2 x 5 days or 25 mg/m2 x 3 days, every 3 weeks) are well tolerated and suitable for further evaluation. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380010 Thu, 18 Mar 2010 22:01:36 +0100 3380010 HIV As a Risk Factor for Lung Cancer in Women: Data From the Women's Interagency HIV Study [AIDS-Related Cancer] http://www.medworm.com/index.php?rid=3380009&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1514%3Frss%3D1 Conclusion HIV infection is strongly associated with smoking behaviors that increase lung cancer risk. The role of HIV itself remains to be clarified. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380009 Thu, 18 Mar 2010 22:01:36 +0100 3380009 Metastasis After Radical Prostatectomy or External Beam Radiotherapy for Patients With Clinically Localized Prostate Cancer: A Comparison of Clinical Cohorts Adjusted for Case Mix [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3380008&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1508%3Frss%3D1 Conclusion Metastatic progression is infrequent in men with low-risk prostate cancer treated with either RP or EBRT. RP patients with higher-risk disease treated had a lower risk of metastatic progression and prostate cancer–specific death than EBRT patients. These results may be confounded by differences in the use and timing of salvage therapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380008 Thu, 18 Mar 2010 22:01:36 +0100 3380008 Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3380007&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1502%3Frss%3D1 Conclusion The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible. Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380007 Thu, 18 Mar 2010 22:01:36 +0100 3380007 Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3380006&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1496%3Frss%3D1 Conclusion AA plus prednisone was well tolerated, with encouraging antitumor activity in heavily pretreated CRPC patients. The incidence of mineralocorticoid-related toxicities (hypertension or hypokalemia) was reduced by adding low-dose prednisone. The combination of AA plus prednisone is recommended for phase III investigations. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380006 Thu, 18 Mar 2010 22:01:36 +0100 3380006 Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3380005&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1489%3Frss%3D1 Conclusion Abiraterone acetate has significant antitumor activity in post-docetaxel patients with CRPC. Randomized, phase III trials of abiraterone acetate are underway to define the future role of this agent. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380005 Thu, 18 Mar 2010 22:01:36 +0100 3380005 Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3380004&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1481%3Frss%3D1 Conclusion Abiraterone acetate was well tolerated and demonstrated activity in CRPC, including in patients previously treated with ketoconazole. Continued clinical study is warranted. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380004 Thu, 18 Mar 2010 22:01:36 +0100 3380004 First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial [Breast Cancer] http://www.medworm.com/index.php?rid=3380003&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1473%3Frss%3D1 Conclusion The HEC regimen is a promising treatment option for patients with HER2-positive MBC. The lower incidence of DLC with HEC, compared with the historic incidence associated with trastuzumab plus doxorubicin, supports further evaluation of the regimen, especially in adjuvant or neoadjuvant settings. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380003 Thu, 18 Mar 2010 22:01:36 +0100 3380003 Aspirin Intake and Survival After Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=3380002&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1467%3Frss%3D1 Conclusion Among women living at least 1 year after a breast cancer diagnosis, aspirin use was associated with a decreased risk of distant recurrence and breast cancer death. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380002 Thu, 18 Mar 2010 22:01:36 +0100 3380002 Alberta Physical Activity and Breast Cancer Prevention Trial: Sex Hormone Changes in a Year-Long Exercise Intervention Among Postmenopausal Women [Breast Cancer] http://www.medworm.com/index.php?rid=3380001&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1458%3Frss%3D1 Conclusion This trial found that previously sedentary postmenopausal women can adhere to a moderate- to vigorous-intensity exercise program that results in changes in estradiol and SHBG concentrations that are consistent with a lower risk for postmenopausal breast cancer. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380001 Thu, 18 Mar 2010 22:01:36 +0100 3380001 Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial [Breast Cancer] http://www.medworm.com/index.php?rid=3380000&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1450%3Frss%3D1 Conclusion In women at elevated familial risk, quality-assured MRI screening shifts the distribution of screen-detected breast cancers toward the preinvasive stage. In women undergoing quality-assured MRI annually, neither mammography, nor annual or half-yearly ultrasound or CBE will add to the cancer yield achieved by MRI alone. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3380000 Thu, 18 Mar 2010 22:01:36 +0100 3380000 Castration-Resistant Prostate Cancer--Hormone Therapy Redux [EDITORIALS] http://www.medworm.com/index.php?rid=3379999&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1447%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379999 Thu, 18 Mar 2010 22:01:36 +0100 3379999 Lifestyle and Breast Cancer Risk: The Way Forward? [EDITORIALS] http://www.medworm.com/index.php?rid=3379998&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1445%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379998 Thu, 18 Mar 2010 22:01:36 +0100 3379998 Early Diagnosis of Hereditary Breast Cancer by Magnetic Resonance Imaging: What Is Realistic? [EDITORIALS] http://www.medworm.com/index.php?rid=3379997&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F9%2F1441%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3379997 Thu, 18 Mar 2010 22:01:36 +0100 3379997 Journal Correction [CORRECTIONS] http://www.medworm.com/index.php?rid=3343452&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1439-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343452 Mon, 08 Mar 2010 23:01:30 +0100 3343452 Journal Correction [CORRECTIONS] http://www.medworm.com/index.php?rid=3343451&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1439%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343451 Mon, 08 Mar 2010 23:01:30 +0100 3343451 Author Correction [CORRECTIONS] http://www.medworm.com/index.php?rid=3343450&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1438-c%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343450 Mon, 08 Mar 2010 23:01:30 +0100 3343450 Author Correction [CORRECTIONS] http://www.medworm.com/index.php?rid=3343449&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1438-b%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343449 Mon, 08 Mar 2010 23:01:30 +0100 3343449 Author Correction [CORRECTIONS] http://www.medworm.com/index.php?rid=3343448&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1438-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343448 Mon, 08 Mar 2010 23:01:30 +0100 3343448 Author Correction [CORRECTIONS] http://www.medworm.com/index.php?rid=3343447&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1438%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343447 Mon, 08 Mar 2010 23:01:30 +0100 3343447 Healing by Cancer [ART OF ONCOLOGY] http://www.medworm.com/index.php?rid=3343446&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1436%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343446 Mon, 08 Mar 2010 23:01:30 +0100 3343446 Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3343445&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1429%3Frss%3D1 Conclusion Treatment with IFN enables discontinuation of imatinib in most patients after prior imatinib/IFN combination therapy and may result in improved molecular response. Induction of a proteinase-3–specific CTL response by IFN may contribute to this effect. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343445 Mon, 08 Mar 2010 23:01:30 +0100 3343445 Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3343444&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1422%3Frss%3D1 Conclusion The combination of weekly bortezomib and rituximab showed significant activity and minimal neurologic toxicity in patients with relapsed WM. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343444 Mon, 08 Mar 2010 23:01:30 +0100 3343444 Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3343443&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1415%3Frss%3D1 Conclusion FDG-PET demonstrated 95.9% accuracy in restaging for patients with HL with CRu/PR after first-line therapy. Given the observed probabilities, FDG-PET is highly cost effective and would reduce costs for the public health care program in Brazil. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343443 Mon, 08 Mar 2010 23:01:30 +0100 3343443 Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3343442&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1408%3Frss%3D1 Conclusion Everolimus has high single-agent activity with an overall response rate of 70% and manageable toxicity in patients with relapsed WM and offers a potential new therapeutic strategy for this patient group. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343442 Mon, 08 Mar 2010 23:01:30 +0100 3343442 Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials [Phase I and Clinical Pharmacology] http://www.medworm.com/index.php?rid=3343441&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1401%3Frss%3D1 Conclusion The derivation of starting dose for first-in-human phase I trials of molecularly targeted agents in patients with cancer is safe but is based on diverse practices using a variety of preclinical toxicologic parameters. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343441 Mon, 08 Mar 2010 23:01:30 +0100 3343441 Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial [Head and Neck Cancer] http://www.medworm.com/index.php?rid=3343440&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1395%3Frss%3D1 Conclusion For T1 or T2 N0 oral squamous cell carcinoma, SLNB with step sectioning and immunohistochemistry, performed by surgeons of mixed experience levels, correctly predicted a pathologically negative neck in 96% of patients (NPV, 96%). (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343440 Mon, 08 Mar 2010 23:01:30 +0100 3343440 Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology] http://www.medworm.com/index.php?rid=3343439&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1387%3Frss%3D1 Conclusion The combination of erlotinib and dasatinib is tolerable, with adverse effects consistent with the two agents. Disease control and inhibition of plasma angiogenesis markers were observed. Personalized strategies for deployment of SFK should receive further attention. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343439 Mon, 08 Mar 2010 23:01:30 +0100 3343439 Mature Results of an Individualized Radiation Dose Prescription Study Based on Normal Tissue Constraints in Stages I to III Non-Small-Cell Lung Cancer [Thoracic Oncology] http://www.medworm.com/index.php?rid=3343438&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1380%3Frss%3D1 Conclusion Individualized prescribed radical radiotherapy based on normal tissue constraints with sequential chemoradiation shows survival rates that come close to results of concurrent chemoradiation schedules, with acceptable acute and late toxicity. A prospective randomized study is warranted to further investigate its efficacy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343438 Mon, 08 Mar 2010 23:01:30 +0100 3343438 Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3343437&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1373%3Frss%3D1 Conclusion Sunitinib did not achieve the predetermined threshold of ≥ 20% activity defined by Response Evaluation Criteria in Solid Tumors. However, antitumor responses were observed, identifying the vascular endothelial growth factor axis as a viable pathway for UC treatment. The reported clinical benefit in previously treated patients warrants further investigation in a disease for which there is no US Food and Drug Administration–approved treatment. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343437 Mon, 08 Mar 2010 23:01:30 +0100 3343437 Facilitating Informed Decisions Regarding Microsatellite Instability Testing Among High-Risk Individuals Diagnosed With Colorectal Cancer [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=3343436&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1366%3Frss%3D1 Conclusion Incorporation of new media education strategies for individuals at risk for LS may be a valuable component of the informed consent process. As clinical criteria for MSI and IHC testing continue to expand, the need for alternative educational approaches to meet this increased demand could be met by the self-administered computer-based strategy that we described. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343436 Mon, 08 Mar 2010 23:01:30 +0100 3343436 Cellular Histone Modification Patterns Predict Prognosis and Treatment Response in Resectable Pancreatic Adenocarcinoma: Results From RTOG 9704 [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=3343435&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1358%3Frss%3D1 Conclusion Cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic adenocarcinoma with distinct epigenetic phenotypes and clinical outcomes and represent prognostic and predictive biomarkers that could inform clinical decisions, including the use of fluorouracil chemotherapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343435 Mon, 08 Mar 2010 23:01:30 +0100 3343435 Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=3343434&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1351%3Frss%3D1 Conclusion The pre-emptive skin treatment regimen was well tolerated. The incidence of specific ≥ grade 2 skin toxicities during the 6-week skin treatment period was reduced by more than 50% in the pre-emptive group compared with the reactive group. Patients in the pre-emptive group reported less QOL impairment than patients in the reactive group. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343434 Mon, 08 Mar 2010 23:01:30 +0100 3343434 Universal Poor Survival in Children With Medulloblastoma Harboring Somatic TP53 Mutations [Pediatric Oncology] http://www.medworm.com/index.php?rid=3343433&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1345%3Frss%3D1 Conclusion Lack of long-term survival in TP53-mutated medulloblastomas highlights the role of TP53 mutations in medulloblastoma resistance to conventional therapies and the need for alternative treatments, and prospective validation of these findings is needed. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343433 Mon, 08 Mar 2010 23:01:30 +0100 3343433 Reply to A.M. Araujo [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3343420&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2Fe132%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343420 Mon, 08 Mar 2010 23:01:30 +0100 3343420 Pemetrexed Plus Bevacizumab for Second-Line Therapy of Non-Small-Cell Lung Cancer: The Importance of Patient Selection [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3343419&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2Fe131%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343419 Mon, 08 Mar 2010 23:01:30 +0100 3343419 Reply to T.J. Smith et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3343418&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2Fe129%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343418 Mon, 08 Mar 2010 23:01:30 +0100 3343418 Comment on Pegylated Liposomal Doxorubicin Plus Docetaxel in Metastatic Breast Cancer [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3343417&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2Fe128%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343417 Mon, 08 Mar 2010 23:01:30 +0100 3343417 Adenocarcinoma of Colon Presenting As Cushing's Syndrome [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=3343416&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2Fe126%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343416 Mon, 08 Mar 2010 23:01:30 +0100 3343416 Whole-Genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-Derived Growth Factor Receptor {alpha} and Poly (ADP-ribose) Polymerase As Potential Therapeutic Targets [Pediatric Oncology] http://www.medworm.com/index.php?rid=3343432&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1337%3Frss%3D1 Conclusion To our knowledge, our data provides the first, comprehensive high-resolution genomic analysis of pediatric DIPG. Our findings of recurrent involvement of the PDGFR pathway as well as defects in DNA repair pathways coupled with gain of PARP-1 highlight two potential, biologically based, therapeutic targets directed specifically at this devastating disease. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343432 Mon, 08 Mar 2010 23:01:29 +0100 3343432 Phase II, Randomized, Open-Label Study of Pegfilgrastim-Supported VDC/IE Chemotherapy in Pediatric Sarcoma Patients [Pediatric Oncology] http://www.medworm.com/index.php?rid=3343431&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1329%3Frss%3D1 Conclusion A single dose of pegfilgrastim at 100 µg/kg administered once per chemotherapy cycle is comparable to daily injections of filgrastim at 5 µg/kg for pediatric sarcoma patients receiving myelosuppressive chemotherapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343431 Mon, 08 Mar 2010 23:01:29 +0100 3343431 Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma [Pediatric Oncology] http://www.medworm.com/index.php?rid=3343430&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1322%3Frss%3D1 Conclusion In our analysis, initial tumor size and tumor response were significant prognostic factors in rhabdomyosarcoma, regardless of whether tumor diameter or volume was considered. Three-dimensional tumor assessment was of no greater prognostic value than one-dimensional assessment, neither initially nor after induction treatment. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343430 Mon, 08 Mar 2010 23:01:29 +0100 3343430 Relationships Between Authorship Contributions and Authors' Industry Financial Ties Among Oncology Clinical Trials [Cancer-Related Complications] http://www.medworm.com/index.php?rid=3343429&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1316%3Frss%3D1 Conclusion Authors who perform key roles in the conception and design, analysis, and interpretation, or reporting of oncology clinical trials are more likely than authors who do not perform such roles to have financial ties to industry. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343429 Mon, 08 Mar 2010 23:01:29 +0100 3343429 Role of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer [Cancer-Related Complications] http://www.medworm.com/index.php?rid=3343428&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1308%3Frss%3D1 Conclusion This study is the first, to our knowledge, to establish a relationship between the radiation dose received by the heart during radiotherapy for a childhood cancer and long-term cardiac mortality. This study also confirms a significant excess risk of cardiac mortality associated with a high cumulative dose of anthracyclines. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343428 Mon, 08 Mar 2010 23:01:29 +0100 3343428 Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=3343427&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1301%3Frss%3D1 Conclusion Oral neratinib showed substantial clinical activity and was reasonably well tolerated among both heavily pretreated and trastuzumab-naïve patients who had advanced, ErbB2-positive breast cancer. Diarrhea was the most common adverse effect but was manageable with antidiarrheal agents and dose modification. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343427 Mon, 08 Mar 2010 23:01:29 +0100 3343427 Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial [Breast Cancer] http://www.medworm.com/index.php?rid=3343426&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1294%3Frss%3D1 Conclusion After 1 year of adjuvant therapy, tamoxifen use is associated with statistically significant lower functioning in verbal memory and executive functioning, whereas exemestane use is not associated with statistically significant lower cognitive functioning in postmenopausal patients with BC. Our results accentuate the need to include assessments of cognitive effects of adjuvant endocrine treatment in long-term safety studies. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343426 Mon, 08 Mar 2010 23:01:29 +0100 3343426 Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients [Breast Cancer] http://www.medworm.com/index.php?rid=3343425&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1287%3Frss%3D1 Conclusion Our results suggest that polymorphisms in CYP2D6 and ABCC2 are important predictors for the prognosis of patients with breast cancer treated with tamoxifen. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343425 Mon, 08 Mar 2010 23:01:29 +0100 3343425 Consistency in Insurance Coverage for Iatrogenic Conditions Resulting From Cancer Treatment Including Fertility Preservation [COMMENTS AND CONTROVERSIES] http://www.medworm.com/index.php?rid=3343424&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1284%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343424 Mon, 08 Mar 2010 23:01:29 +0100 3343424 Authorship and Industry Financial Relationships: The Tie That Binds [EDITORIALS] http://www.medworm.com/index.php?rid=3343423&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1281%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343423 Mon, 08 Mar 2010 23:01:29 +0100 3343423 Cardiotoxicity After Childhood Cancer: Beginning With the End in Mind [EDITORIALS] http://www.medworm.com/index.php?rid=3343422&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1276%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343422 Mon, 08 Mar 2010 23:01:29 +0100 3343422 Evidence and Practice Regarding the Role for CYP2D6 Inhibition in Decisions About Tamoxifen Therapy [EDITORIALS] http://www.medworm.com/index.php?rid=3343421&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F8%2F1273%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3343421 Mon, 08 Mar 2010 23:01:29 +0100 3343421 Reply to A. Stang et al, J.T. Rowley et al, and F. Samkange-Zeeb et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3303589&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe124%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303589 Wed, 24 Feb 2010 23:01:04 +0100 3303589 Comparison of Studies on Mobile Phone Use and Risk of Tumors [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3303588&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe123%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303588 Wed, 24 Feb 2010 23:01:04 +0100 3303588 Studies of Mobile Phone Use and Brain Tumor Risk Are Independent of Industry Influence [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3303587&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe122%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303587 Wed, 24 Feb 2010 23:01:04 +0100 3303587 Arbitrary Results of a Meta-Analysis on Cancer Risks Among Mobile Phone Users [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3303586&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe121%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303586 Wed, 24 Feb 2010 23:01:04 +0100 3303586 Reply to T. Watanabe et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3303585&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe120%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303585 Wed, 24 Feb 2010 23:01:04 +0100 3303585 Prognostic Significance of 18q Loss of Heterzygosity in Microsatellite-Stable Colorectal Cancer [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3303584&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe119%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303584 Wed, 24 Feb 2010 23:01:04 +0100 3303584 Cancer and the Family: The Silent Words of Truth [ART OF ONCOLOGY] http://www.medworm.com/index.php?rid=3303619&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1269%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303619 Wed, 24 Feb 2010 23:01:03 +0100 3303619 Ephraim McDowell, the First Ovariotomy, and the Birth of Abdominal Surgery [HISTORY OF ONCOLOGY] http://www.medworm.com/index.php?rid=3303618&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1262%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303618 Wed, 24 Feb 2010 23:01:03 +0100 3303618 Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer [BIOLOGY OF NEOPLASIA] http://www.medworm.com/index.php?rid=3303617&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1254%3Frss%3D1 Personalized cancer medicine based on the genetic milieu of individual colorectal tumors has long been postulated, but until recently this concept was not supported by clinical evidence. The advent of the epidermal growth factor receptor (EGFR) –targeted monoclonal antibodies cetuximab and panitumumab has paved the way to the individualized treatment of metastatic colorectal cancer (mCRC). Here we discuss the evidence that mCRCs respond differently to EGFR-targeted agents and that the tumor-specific response has a genetic basis. We outline how, from the initial observation that cetuximab or panitumumab as monotherapy is effective only in 10% to 20% of mCRCs, knowledge has being gained on the molecular mechanisms underlying primary resistance to these agents. The role of oncogenic act... Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303617 Wed, 24 Feb 2010 23:01:03 +0100 3303617 Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients [Sarcomas] http://www.medworm.com/index.php?rid=3303616&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1247%3Frss%3D1 Conclusion This analysis confirms a small PFS advantage of high-dose imatinib, essentially among patients with KIT exon 9 mutations, but no OS advantage. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303616 Wed, 24 Feb 2010 23:01:03 +0100 3303616 Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology Group [Pediatric Oncology] http://www.medworm.com/index.php?rid=3303615&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1240%3Frss%3D1 Conclusion These data support further evaluation of RMS metagenes to discriminate patients with good prognosis from those with poor prognosis, with the potential to direct risk-adapted therapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303615 Wed, 24 Feb 2010 23:01:03 +0100 3303615 Second Malignant Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low-Dose Radiation and Chemotherapy [Pediatric Oncology] http://www.medworm.com/index.php?rid=3303614&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1232%3Frss%3D1 Conclusion Despite treatment with low-dose radiation, children treated for HL remain at significant risk for SMN. Sarcomas, breast and thyroid carcinomas occurred with similar frequency and latency as found in studies of children with HL who received high-dose radiation. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303614 Wed, 24 Feb 2010 23:01:03 +0100 3303614 Temporal Trends in Cause-Specific Late Mortality Among 5-Year Survivors of Childhood Cancer [Pediatric Oncology] http://www.medworm.com/index.php?rid=3303613&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1224%3Frss%3D1 Conclusion While overall patterns of mortality from other health conditions do not differ over time, adjustment for demographic characteristics provides evidence that risk of treatment-related mortality may be lower in more recent eras. Disparities in health care utilization among survivors should be explored. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303613 Wed, 24 Feb 2010 23:01:03 +0100 3303613 Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Gynecologic Cancer] http://www.medworm.com/index.php?rid=3303612&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1215%3Frss%3D1 Conclusion Pertuzumab may add activity to gemcitabine for the treatment of platinum-resistant ovarian cancer. Low HER3 mRNA expression may predict pertuzumab clinical benefit and be a valuable prognostic marker. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303612 Wed, 24 Feb 2010 23:01:03 +0100 3303612 Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3303611&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1209%3Frss%3D1 Conclusion These long-term follow-up data of transplantation trials provide a crucial framework of reference for outcome reporting of novel agent–based trials reportedly exhibiting remarkable short-term efficacy approaching high-dose therapy results. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303611 Wed, 24 Feb 2010 23:01:03 +0100 3303611 End-of-Life Discussions, Goal Attainment, and Distress at the End of Life: Predictors and Outcomes of Receipt of Care Consistent With Preferences [Palliative and Supportive Care] http://www.medworm.com/index.php?rid=3303610&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1203%3Frss%3D1 Conclusion Patients with cancer are more likely to receive EOL care that is consistent with their preferences when they have had the opportunity to discuss their wishes for EOL care with a physician. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303610 Wed, 24 Feb 2010 23:01:03 +0100 3303610 Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery [Melanoma] http://www.medworm.com/index.php?rid=3303609&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1196%3Frss%3D1 Conclusion Chemotherapy-induced lymphodepletion modulates the homeostatic repopulation of the lymphocyte compartment and influences recovering lymphocyte subpopulations. Clinical activity seems similar to standard high-dose aldesleukin alone. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303609 Wed, 24 Feb 2010 23:01:03 +0100 3303609 Positron Emission Tomography With [18F]Fluorodeoxyglucose Improves Staging and Patient Management in Patients With Head and Neck Squamous Cell Carcinoma: A Multicenter Prospective Study [Head and Neck Cancer] http://www.medworm.com/index.php?rid=3303608&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1190%3Frss%3D1 Conclusion Adding whole-body PET-FDG to the pretherapeutic conventional staging of HNSCC improved the TNM classification of the disease and altered the management of 13.7% of patients. These findings support the implementation of PET-FDG in the routine imaging work-up of HNSCC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303608 Wed, 24 Feb 2010 23:01:03 +0100 3303608 Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=3303607&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1181%3Frss%3D1 Conclusion Biomarker analysis supported the functional equivalence of weekly and every second week administration of cetuximab and provided further confirmation that patients with KRAS wild-type mCRC were those most likely to benefit from cetuximab treatment. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303607 Wed, 24 Feb 2010 23:01:03 +0100 3303607 Reply to K. Filanovsky et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3303583&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe117%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303583 Wed, 24 Feb 2010 23:01:03 +0100 3303583 Advantage of MIDAM Protocol in Treatment of Elderly Patients With Refractory and Relapsing Acute Myeloid Leukemia [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3303582&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe115%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303582 Wed, 24 Feb 2010 23:01:03 +0100 3303582 Merkel Cell Carcinoma in the Peripheral Blood of a Patient With Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=3303581&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe113%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303581 Wed, 24 Feb 2010 23:01:03 +0100 3303581 Favorable Response to Erlotinib in a Lung Adenocarcinoma With Both Epidermal Growth Factor Receptor Exon 19 Deletion and K-ras G13D Mutations [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=3303580&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2Fe111%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303580 Wed, 24 Feb 2010 23:01:03 +0100 3303580 Decision Model of Segmental Compared With Total Abdominal Colectomy for Colon Cancer in Hereditary Nonpolyposis Colorectal Cancer [Surgical Oncology] http://www.medworm.com/index.php?rid=3303606&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1175%3Frss%3D1 Conclusion SEG and TAC are approximately equivalent strategies for patients with colon cancer and Lynch syndrome. The decision regarding which operation is preferable should be made on the basis of patient factors and preferences, with special emphasis on age and the ability of the patient to utilize intensive surveillance. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303606 Wed, 24 Feb 2010 23:01:02 +0100 3303606 Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma [Neurooncology] http://www.medworm.com/index.php?rid=3303605&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1168%3Frss%3D1 Conclusion Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303605 Wed, 24 Feb 2010 23:01:02 +0100 3303605 Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor-Positive Breast Cancer in Postmenopausal Women [Breast Cancer] http://www.medworm.com/index.php?rid=3303604&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1161%3Frss%3D1 Conclusion Plasma E2 levels are significantly associated with gene expression of ER-positive breast cancers and should be considered in future genomic studies of ER-positive breast cancer. The AvERG is a new experimental tool for the study of putative estrogenic stimuli of breast cancer. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303604 Wed, 24 Feb 2010 23:01:02 +0100 3303604 Randomized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor-Associated Joint Symptoms in Women With Early-Stage Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=3303603&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1154%3Frss%3D1 Conclusion Women with AI-induced arthralgias treated with TA had significant improvement of joint pain and stiffness, which was not seen with SA. Acupuncture is an effective and well-tolerated strategy for managing this common treatment-related side effect. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303603 Wed, 24 Feb 2010 23:01:02 +0100 3303603 Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=3303602&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1145%3Frss%3D1 Conclusion Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303602 Wed, 24 Feb 2010 23:01:02 +0100 3303602 Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [Breast Cancer] http://www.medworm.com/index.php?rid=3303601&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1138%3Frss%3D1 Conclusion The combination of pertuzumab and trastuzumab is active and well tolerated in patients with metastatic HER2-positive breast cancer who had experienced progression during prior trastuzumab therapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303601 Wed, 24 Feb 2010 23:01:02 +0100 3303601 Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=3303600&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1131%3Frss%3D1 Conclusion The limited efficacy observed in this study, generally SD of relatively short duration, suggested little benefit of further investigation of single-agent pertuzumab in unselected patients with HER2-negative disease. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303600 Wed, 24 Feb 2010 23:01:02 +0100 3303600 Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=3303599&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1124%3Frss%3D1 Conclusion Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastuzumab significantly improved PFS and CBR versus lapatinib alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303599 Wed, 24 Feb 2010 23:01:02 +0100 3303599 Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3303598&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1117%3Frss%3D1 Conclusion Substantial variation exists in management of localized prostate cancer that is not explained by measurable factors. A critical need exists for high-quality comparative effectiveness research in localized prostate cancer to help guide treatment decision making. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303598 Wed, 24 Feb 2010 23:01:02 +0100 3303598 Finasteride to Prevent Prostate Cancer: Should All Men or Only a High-Risk Subgroup Be Treated? [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3303597&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1112%3Frss%3D1 Conclusion Clinicians wishing to reduce the risk of any biopsy-detectable prostate cancer should recommend finasteride to all men. Clinicians who believe that it is unnecessary to prevent all cancers, but that preventing those readily detectable by screening would be desirable, would be best off recommending finasteride only to a high-risk subgroup. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303597 Wed, 24 Feb 2010 23:01:02 +0100 3303597 Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09 [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3303596&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1106%3Frss%3D1 Conclusion This randomized controlled trial shows superior long-term cancer control for men with localized prostate cancer receiving high-dose versus conventional-dose radiation. This was achieved without an increase in grade ≥ 3 late urinary or rectal morbidity. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303596 Wed, 24 Feb 2010 23:01:02 +0100 3303596 Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3303595&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1099%3Frss%3D1 Conclusion PROSTVAC-VF immunotherapy was well tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in median OS in men with mCRPC. These provocative data provide preliminary evidence of clinically meaningful benefit but need to be confirmed in a larger phase III study. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303595 Wed, 24 Feb 2010 23:01:02 +0100 3303595 Enzastaurin in the Treatment of Recurrent Glioblastoma: A Promise That Did Not Materialize [EDITORIALS] http://www.medworm.com/index.php?rid=3303594&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1097%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303594 Wed, 24 Feb 2010 23:01:02 +0100 3303594 Whither HER2-Related Therapeutics? [EDITORIALS] http://www.medworm.com/index.php?rid=3303593&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1091%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303593 Wed, 24 Feb 2010 23:01:02 +0100 3303593 Optimizing the Delivery of Targeted Research: An Opportunity for Comparative Effectiveness Research [EDITORIALS] http://www.medworm.com/index.php?rid=3303592&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1089%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303592 Wed, 24 Feb 2010 23:01:02 +0100 3303592 Seduced by Dose? [EDITORIALS] http://www.medworm.com/index.php?rid=3303591&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1087%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303591 Wed, 24 Feb 2010 23:01:02 +0100 3303591 Developing Immunotherapy As Legitimate Therapy for Patients With Prostate Cancer [EDITORIALS] http://www.medworm.com/index.php?rid=3303590&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F7%2F1085%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3303590 Wed, 24 Feb 2010 23:01:01 +0100 3303590 Breast Cancer Pathology Report: In Response to Zurrida et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3285042&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe110%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285042 Thu, 18 Feb 2010 23:00:39 +0100 3285042 Successful Treatment With Meloxicam, a Cyclooxygenase-2 Inhibitor, of Patients With Extra-Abdominal Desmoid Tumors: A Pilot Study [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3285041&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe107%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285041 Thu, 18 Feb 2010 23:00:39 +0100 3285041 Reply to M.S. Katz et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3285040&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe106%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285040 Thu, 18 Feb 2010 23:00:39 +0100 3285040 Central Institutional Review Board-Facilitated Review Metrics Omit Critical Components [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3285039&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe105%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285039 Thu, 18 Feb 2010 23:00:39 +0100 3285039 Reply to P.E. Lonning et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3285038&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe103%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285038 Thu, 18 Feb 2010 23:00:39 +0100 3285038 Endocrine Effects of Aromatase Inhibitors [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3285037&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe101%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285037 Thu, 18 Feb 2010 23:00:39 +0100 3285037 Reply to S. Kilickap et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3285036&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe100%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285036 Thu, 18 Feb 2010 23:00:39 +0100 3285036 Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma [CORRESPONDENCE] http://www.medworm.com/index.php?rid=3285035&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe99%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285035 Thu, 18 Feb 2010 23:00:39 +0100 3285035 Primary Gonadal Germ Cell Tumor Associated With Acute Leukemia With Common Cytogenetics [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=3285034&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe96%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285034 Thu, 18 Feb 2010 23:00:39 +0100 3285034 Presentation of Extranodal Natural Killer T-Cell Lymphoma, Nasal Type, With Poorly Circumscribed Erythematous Patches [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=3285033&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe94%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285033 Thu, 18 Feb 2010 23:00:39 +0100 3285033 The PI3K Pathway As Drug Target in Human Cancer [BIOLOGY OF NEOPLASIA] http://www.medworm.com/index.php?rid=3285070&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1075%3Frss%3D1 The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metabolism. This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components. In addition, PI3K signaling may serve integral functions for noncancerous cells in the tumor microenvironment. Consequently, therapeutics targeting the PI3K pathway are being developed at a rapid pace, and preclinical and early clinical studies are beginning to suggest specific strategies to effectively use them. However, the central role of PI3K signaling in a large array of diverse biologic processes raises concerns about its use in therapeutics and increases the need to develop sophisticated strategies for its use. In t... Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285070 Thu, 18 Feb 2010 23:00:38 +0100 3285070 Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3285069&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1069%3Frss%3D1 Conclusion There is a statistically significant difference in primary treatment for prostate cancer between African American and white men with similar risk profiles. Additional research on the influence of patient/physician education and perception and the role that socioeconomic factors play in mortality from prostate cancer may be areas of focus for public health initiatives. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285069 Thu, 18 Feb 2010 23:00:38 +0100 3285069 Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3285068&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1061%3Frss%3D1 Conclusion Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285068 Thu, 18 Feb 2010 23:00:38 +0100 3285068 Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study [Genitourinary Cancer] http://www.medworm.com/index.php?rid=3285067&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1054%3Frss%3D1 Conclusion Sarcopenia is prevalent in patients with metastatic RCC and is an occult condition in patients with normal or high BMI. Muscle loss is specifically exacerbated by sorafenib, consistent with the evidence for a role of kinases in regulating muscle mass. Muscle loss is a sorafenib adverse effect that may relate to asthenia, fatigue, and physical disability. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285067 Thu, 18 Feb 2010 23:00:38 +0100 3285067 Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3285066&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1047%3Frss%3D1 Conclusion These data, combined with other recent studies using ATO in the primary management of APL, demonstrate the important role that ATO can play in the primary management of this curable disease. Future studies should continue to focus on reducing the toxicity of treatment without increasing the relapse rate. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285066 Thu, 18 Feb 2010 23:00:38 +0100 3285066 Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3285065&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1038%3Frss%3D1 Conclusion This large, multicenter, retrospective analysis suggests significantly improved PFS and OS associated with early rituximab-based treatment in PTLD. In addition, clinical factors at diagnosis identified patients with markedly divergent outcomes. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285065 Thu, 18 Feb 2010 23:00:38 +0100 3285065 Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3285064&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1031%3Frss%3D1 Conclusion Bortezomib with or without dexamethasone is active in AL amyloidosis and induces rapid responses and high rates of hematologic and organ responses. Serial measurement of cardiac biomarkers is a powerful predictor of outcome. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285064 Thu, 18 Feb 2010 23:00:38 +0100 3285064 Evaluation of Coronary Artery Disease by Computed Tomography Angiography in Patients Treated for Childhood Hodgkin's Lymphoma [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3285063&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1025%3Frss%3D1 Conclusion To our knowledge, this is the first large study using CTA for detection of coronary abnormalities in patients treated for HL in pediatric age group. Coronary CTA is a minimally invasive tool for early diagnosis of coronary artery disease in patients who were treated with mediastinal radiotherapy and/or cardiotoxic chemotherapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285063 Thu, 18 Feb 2010 23:00:38 +0100 3285063 Hypoxia-Inducible Factor-1 {alpha} Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3285062&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1017%3Frss%3D1 Conclusion The expression of HIF-1 protein is an important independent favorable prognostic factor for survival in patients with DLBCL treated with R-CHOP. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285062 Thu, 18 Feb 2010 23:00:38 +0100 3285062 Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation [Hematologic Malignancies] http://www.medworm.com/index.php?rid=3285061&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1011%3Frss%3D1 Conclusion Patients who have survived for at least 5 years after hematopoietic cell transplantation without recurrence of the original disease have a high probability of surviving for an additional 15 years, but life expectancy is not fully restored. Further effort is needed to reduce the burden of disease and treatment-related complications in this population. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285061 Thu, 18 Feb 2010 23:00:38 +0100 3285061 Migraine History and Breast Cancer Risk Among Postmenopausal Women [Breast Cancer] http://www.medworm.com/index.php?rid=3285060&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F1005%3Frss%3D1 Conclusion This study supports the hypothesis that a history of migraine is associated with a lower risk of breast cancer and that this relationship is independent of recent NSAID use. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285060 Thu, 18 Feb 2010 23:00:38 +0100 3285060 Nodal-Stage Classification in Invasive Lobular Breast Carcinoma: Influence of Different Interpretations of the pTNM Classification [Breast Cancer] http://www.medworm.com/index.php?rid=3285059&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F999%3Frss%3D1 Conclusion Compared with the guidelines by Turner et al, the EWGBSP definitions better reflect SN metastatic tumor load and allow better differentiation between patients with lobular breast carcinoma who have a limited or a high risk of non-SN metastases. Therefore, we suggest using the EWGBSP definitions in these patients to select high-risk patients who may benefit from additional local and/or systemic therapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285059 Thu, 18 Feb 2010 23:00:38 +0100 3285059 Exercise, Tea Consumption, and Depression Among Breast Cancer Survivors [Breast Cancer] http://www.medworm.com/index.php?rid=3285058&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F991%3Frss%3D1 Conclusion Regular exercise participation and tea consumption may play an important role in the prevention of depression among breast cancer survivors. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285058 Thu, 18 Feb 2010 23:00:38 +0100 3285058 HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients [Breast Cancer] http://www.medworm.com/index.php?rid=3285057&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F984%3Frss%3D1 Conclusion The 2T profile is a more accurate predictor of incremental benefit from anthracycline-containing chemotherapy than HER2, TIMP-1, or TOP2A individually, and compared with these, 2T classifies a larger proportion of patients as sensitive to anthracyclines. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285057 Thu, 18 Feb 2010 23:00:38 +0100 3285057 Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=3285032&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2Fe91%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285032 Thu, 18 Feb 2010 23:00:38 +0100 3285032 Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=3285056&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F976%3Frss%3D1 Conclusion HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285056 Thu, 18 Feb 2010 23:00:37 +0100 3285056 Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial [Breast Cancer] http://www.medworm.com/index.php?rid=3285055&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F967%3Frss%3D1 Conclusion In postmenopausal women at risk of fragility fracture who were receiving adjuvant anastrozole for EBC, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable effects in BMD during 24 months. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285055 Thu, 18 Feb 2010 23:00:37 +0100 3285055 Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady-State Serum Concentrations and Is Well Tolerated [Breast Cancer] http://www.medworm.com/index.php?rid=3285054&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F960%3Frss%3D1 Conclusion An intensive loading regimen of trastuzumab achieved higher-than-steady–state serum concentrations during cycle 1, was well tolerated, and had a good efficacy profile. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285054 Thu, 18 Feb 2010 23:00:37 +0100 3285054 NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia [Pediatric Oncology] http://www.medworm.com/index.php?rid=3285053&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F955%3Frss%3D1 Conclusion Low-dose immunosuppression followed by donor-recipient inhibitory KIR-HLA mismatched NK cells is well tolerated by patients and results in successful engraftment. We propose to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increasing mortality in children with AML. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285053 Thu, 18 Feb 2010 23:00:37 +0100 3285053 Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599 [Thoracic Oncology] http://www.medworm.com/index.php?rid=3285052&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F949%3Frss%3D1 Conclusion Data from ECOG 4599 suggest that onset of HBP during treatment with PCB may be associated with improved outcomes, and additional studies of the downstream effects of VEGF suppression and hypertension are needed. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285052 Thu, 18 Feb 2010 23:00:37 +0100 3285052 Phase II Trial of a Trimodality Regimen for Stage III Non-Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study [Thoracic Oncology] http://www.medworm.com/index.php?rid=3285051&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F942%3Frss%3D1 Conclusion Staging and treatment with chemoradiotherapy and complete resection performed in experienced centers achieve acceptable morbidity and mortality. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285051 Thu, 18 Feb 2010 23:00:37 +0100 3285051 Reduction of Elevated Plasma Osteopontin Levels With Resection of Non-Small-Cell Lung Cancer [Thoracic Oncology] http://www.medworm.com/index.php?rid=3285050&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F936%3Frss%3D1 Conclusion Plasma OPN levels are elevated in early-stage NSCLC. They are reduced after resection and appear to increase with recurrence. Plasma OPN may have utility as a biomarker in early-stage NSCLC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285050 Thu, 18 Feb 2010 23:00:37 +0100 3285050 Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer [Thoracic Oncology] http://www.medworm.com/index.php?rid=3285049&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F928%3Frss%3D1 Conclusion Both lung SBRT and wedge resection are reasonable treatment options for stage I NSCLC patients ineligible for anatomic lobectomy. SBRT reduced LR, RR, and LRR. In this nonrandomized population of patients selected for surgery versus SBRT (medically inoperable) at physician discretion, OS was higher in surgical patients. SBRT and surgery, however, had identical CSS. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285049 Thu, 18 Feb 2010 23:00:37 +0100 3285049 Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology] http://www.medworm.com/index.php?rid=3285048&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F918%3Frss%3D1 Conclusion In contrast with colorectal cancer, and within the limitations of the data set, efficacy parameters did not appear to correlate with K-Ras mutation status or with any of the EGFR-related biomarkers evaluated. Additional exploratory analyses are essential to identify predictive markers and to optimize patient selection for cetuximab therapy in NSCLC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285048 Thu, 18 Feb 2010 23:00:37 +0100 3285048 Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099 [Thoracic Oncology] http://www.medworm.com/index.php?rid=3285047&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F911%3Frss%3D1 Conclusion The addition of cetuximab to TC did not significantly improve the primary end point, PFS-IRRC. There was significant improvement in ORR by IRRC. The difference in OS favored cetuximab but did not reach statistical significance. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285047 Thu, 18 Feb 2010 23:00:37 +0100 3285047 Natural Killer Cell Consolidation for Acute Myelogenous Leukemia: A Cell Therapy Ready for Prime Time? [EDITORIALS] http://www.medworm.com/index.php?rid=3285046&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F909%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285046 Thu, 18 Feb 2010 23:00:37 +0100 3285046 Surgery Versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer: Who's Down for the Count? [EDITORIALS] http://www.medworm.com/index.php?rid=3285045&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F907%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285045 Thu, 18 Feb 2010 23:00:37 +0100 3285045 Stereotactic Body Radiation Therapy Versus Wedge Resection for Medically Inoperable Stage I Lung Cancer: Tailored Therapy or One Size Fits All? [EDITORIALS] http://www.medworm.com/index.php?rid=3285044&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F28%2F6%2F905%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=3285044 Thu, 18 Feb 2010 23:00:37 +0100 3285044